Venture capital firm

BVCF Management

China-focused life sciences investment fund manager founded to build global Chinese healthcare companies

Write a review

China
Shanghai
Hong Kong
Investment Management
+7 more

Visit Website Get introducedRequest an introduction Write a Review

Own this listing? Claim it

TrustList summary

BVCF Management runs BioVeda China Fund, which has invested in life sciences since 2005. The fund's stated aim is to create and develop Chinese life science companies with a global reach. Its investors include global institutions and strategic backers.

Products and services

Life sciences investment: funding for Chinese healthcare and biotech companies.
Forward-looking strategy: an investment approach based on technology, policy and market insight.
Experienced team: a seasoned investment team.

Clients

Life science companies in China, plus financial and strategic investors around the world who back the fund. It says it wants to help China build global life science companies in coming decades.

Key facts

Founded: 2005
Fund: BioVeda China Fund
Focus: Chinese life sciences companies

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Rankings

BVCF Management is ranked on 6 TrustList rankings: #5 on 1, #6 on 1, #11 on 1, #12 on 1, #15 on 1 and #22 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. BVCF Management has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Venture capital firm · 6 rankings

#5of 27
China
It is the only one of the 27 here listing biotech and investment management.
Its profile: “BVCF Management runs BioVeda China Fund, which has invested in life sciences since 2005.”
Of the 27 here, 8 also cover partners and 6 also cover series; 9 also work in Shanghai and 7 also work in Beijing.
Behind China Universal, ahead of Keytone Ventures.
#6of 45
Shanghai
It is one of 2 here listing science and series.
Of the 45 here, 6 also cover healthtech and 5 also cover banking; 25 also work in Hong Kong and 14 also work in New York City.
Behind China Universal, ahead of Moelis Australia.
#11of 79
Biotech investors
It is one of 11 here listing series a and one of 22 here listing healthtech.
Of the top 65 here, 17 also cover science and 11 also cover series a; 14 also work in Boston and 13 also work in San Francisco.
Behind 5AM Ventures, ahead of Hercules Technology Growth Capital Inc.
#12of 69
Hong kong
It is one of 3 here listing investment management and one of 4 here listing biotech.
Of the top 59 here, 6 also cover fintech; 24 also work in London and 15 also work in Tokyo.
Behind Brevan Howard, ahead of Moelis Australia.
#15of 246
Series a
It is the only one of the top 57 here listing investment management and one of 3 here listing biotech.
Of the top 57 here, 21 also cover seed stage and 16 also cover pre seed; 5 also work in Silicon Valley and 4 also work in Sao Paulo.
Behind Startup Capital Ventures, ahead of MMC Ventures.
#22of 147
Healthtech investors
It is the only one of the top 64 here listing investment management and one of 7 here listing science.
Of the top 64 here, 14 also cover biotech and 13 also cover growth stage; 7 also work in Chicago.
Behind Claremont Creek Ventures, ahead of Beecken Petty O’Keefe & Company.